Camp - CAMP

Option chain shows key data for Camp4 Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Camp4 Therapeutics.

Camp4 Therapeutics (NASDAQ:CAMP) Stock, Option Chain

Camp4 Therapeutics

CalAmp

Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.

CAMP

NAGE

SNDK

XPRO

This Sandisk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Markets

Movers

Trading Ideas

AIFU

BLMZ

BRCC

CDZI

DGLY

ENGS

GPUS

JBDI

MRIN

NCNA

NITO

PLTR

PONY

RCUS

SXTC

TDUP

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

Healthcare Workers Sound the Alarm

Long Ideas

Pre-Market Outlook

EWTX

GNFT

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics Corp

CalAmp Corp

Campbell International Holding Corp

CAMPBELL RES INC by Campbell Resources Inc.

Campbell Resources Inc

Camping World Holdings, Inc. Class A Common Stock

Camping World Holdings Inc

Health Care

Management

Press Releases

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMP4 to Participate in Upcoming Investor Conferences

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

Earnings

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

General

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

KRRO

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

BioAtla

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kala Bio

Kezar Life Sciences

Lantern Pharma

Nanoviricides

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Passage Bio

Pluri

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Vor Biopharma

Xilio Therapeutics

Wedbush

Leerink Partners

JP Morgan

Piper Sandler

Goldman Sachs

Comments

Camp4 Therapeutics

Camp4 Therapeutics (CAMP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell